SUTENT Demonstrated More Than 10 Months' Median Progression-Free Survival (PFS)
The independent DMC recommended study termination prior to the pre-specified interim analysis, which may have led to an overestimate of the magnitude of PFS effect
Fewer deaths had occurred in the SUTENT arm at the time of the primary analysis
- 9 deaths in patients treated with SUTENT vs 21 deaths in patients given placebo
- OS data were not mature at the time of this analysis
Statistically significant difference in ORR vs placebo
- 9.3% with SUTENT vs 0% with placebo (95% CI: 3.2, 15.4; P=.0066)
SUTENT is approved for advanced unresectable pNET.
